Evidence map›Paper›PMID 39697063›Full record

ArticleAnnals of medicine2025

Severe interstitial lung disease risk prediction in anti-melanoma differentiation-associated protein 5 positive dermatomyositis: the STRAD-Ro52 model.

Fei Xiao, Feilong Chen, DongSheng Li, Songyuan Zheng, Xiao Liang, Juan Wu, JunYuan Zhong, Xiangliang Tan, Rui Chen, Junqing Zhu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fei XiaoDepartment of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Feilong ChenSouthern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University, Guangzhou, China.
DongSheng LiDepartment of Rheumatology and Immunology, People's Hospital of Ganzhou City, Ganzhou, China.
Songyuan ZhengDepartment of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiao LiangDepartment of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Juan WuDepartment of Rheumatology and Immunology, People's Hospital of Ganzhou City, Ganzhou, China.
JunYuan ZhongDepartment of Medical Imaging, People's Hospital of Ganzhou City, Ganzhou, China.
Xiangliang TanDepartment of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Rui ChenDepartment of Biology, School of Life and Health, Hainan University, Haikou, China.
Junqing ZhuDepartment of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Shixian ChenDepartment of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Juan LiDepartment of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID 0000-0002-2977-2966

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAnti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated interstitial lung disease (MDA5

methodsWe developed a 'Standardized Threshold Ratio Analysis & Distribution' (STRAD) to analyse lung HRCT images. In this retrospective study, 51 patients with MDA5

resultsSignificant differences were observed between the two groups in STRAD parameters, anti-Ro52 antibody titers, presence of anti-Ro52 antibodies, age, ESR, ALB, Pa/FiO

conclusionsThe STRAD-Ro52 model assists in identifying MDA5

Indexed as

DermatomyositisInterferon-Induced Helicase, IFIH1Lung Diseases, InterstitialTomography, X-Ray ComputedAdultAgedAutoantibodiesFemaleHumansMaleMiddle AgedRetrospective StudiesRibonucleoproteinsRisk AssessmentRisk FactorsSeverity of Illness IndexAutoantibodiesIFIH1 protein, humanInterferon-Induced Helicase, IFIH1RibonucleoproteinsSS-A Antigenanti-melanoma differentiation-associated protein 5 antibodycomputed tomographyDermatomyositisrisk modelsevere interstitial lung diseaseStandardized Threshold Ratio Analysis & Distribution

Identifiers

PMID39697063
PMCPMC11660418

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.